Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Altmann

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Neurocritical Care|August 3, 2021
Prediction of Neurological Recovery After Cardiac Arrest Using Neurofilament Light Chain is Improved by a Proteomics-Based Multimarker PanelRaphael Wurm, Henrike Arfsten, Besnik Muqaku, et al.
Frontiers in Aging Neuroscience|September 8, 2022
Real-world applicability of glial fibrillary acidic protein and neurofilament light chain in Alzheimer's diseaseTandis Parvizi, Theresa König, Raphael Wurm, et al.
Journal of Neuroinflammation|March 19, 2020
Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndromePatrick Altmann, Desiree De Simoni, Alexandra Kaider, et al.
Journal of Neurology|April 19, 2023
Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)Tobias Monschein, Sarinah Dekany, Tobias Zrzavy, et al.
Journal of Neurology|June 5, 2023
Correction: Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)Tobias Monschein, Sarinah Dekany, Tobias Zrzavy, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 14, 2022
Olfactory threshold predicts treatment response in relapsing multiple sclerosisGabriel Bsteh, Harald Hegen, Klaus Berek, et al.
European Journal of Neurology|October 24, 2024
Treating to target in multiple sclerosis: Do we know how to measure whether we hit it?Gabriel Bsteh, Nik Krajnc, Patrick Altmann, et al.
Frontiers in Neurology|May 1, 2024
Immunophenotyping in routine clinical practice for predicting treatment response and adverse events in patients with MSTobias Zrzavy, Kerstin Rieder, Viktoria Wuketich, et al.
Nano Letters|February 16, 2021
Phonon-Mediated Interlayer Charge Separation and Recombination in a MoSe<sub>2</sub>/WSe<sub>2</sub> HeterostructureZilong Wang, Patrick Altmann, Christoph Gadermaier, et al.
Experimental Neurology|March 24, 2015
The secretome of apoptotic human peripheral blood mononuclear cells attenuates secondary damage following spinal cord injury in ratsThomas Haider, Romana Höftberger, Beate Rüger, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Neurocritical Care|August 3, 2021
Prediction of Neurological Recovery After Cardiac Arrest Using Neurofilament Light Chain is Improved by a Proteomics-Based Multimarker PanelRaphael Wurm, Henrike Arfsten, Besnik Muqaku, et al.
Frontiers in Aging Neuroscience|September 8, 2022
Real-world applicability of glial fibrillary acidic protein and neurofilament light chain in Alzheimer's diseaseTandis Parvizi, Theresa König, Raphael Wurm, et al.
Journal of Neuroinflammation|March 19, 2020
Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndromePatrick Altmann, Desiree De Simoni, Alexandra Kaider, et al.
Journal of Neurology|April 19, 2023
Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)Tobias Monschein, Sarinah Dekany, Tobias Zrzavy, et al.
Journal of Neurology|June 5, 2023
Correction: Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)Tobias Monschein, Sarinah Dekany, Tobias Zrzavy, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 14, 2022
Olfactory threshold predicts treatment response in relapsing multiple sclerosisGabriel Bsteh, Harald Hegen, Klaus Berek, et al.
European Journal of Neurology|October 24, 2024
Treating to target in multiple sclerosis: Do we know how to measure whether we hit it?Gabriel Bsteh, Nik Krajnc, Patrick Altmann, et al.
Frontiers in Neurology|May 1, 2024
Immunophenotyping in routine clinical practice for predicting treatment response and adverse events in patients with MSTobias Zrzavy, Kerstin Rieder, Viktoria Wuketich, et al.
Nano Letters|February 16, 2021
Phonon-Mediated Interlayer Charge Separation and Recombination in a MoSe<sub>2</sub>/WSe<sub>2</sub> HeterostructureZilong Wang, Patrick Altmann, Christoph Gadermaier, et al.
Experimental Neurology|March 24, 2015
The secretome of apoptotic human peripheral blood mononuclear cells attenuates secondary damage following spinal cord injury in ratsThomas Haider, Romana Höftberger, Beate Rüger, et al.
Pageof 6